Resources

Your selections:

Clear all

Show Filters

We found 278 resources that match your search.

DAIDS Therapeutic Research Program Template for Pregnancy Prevention

DAIDS Therapeutic Research Program protocol eligibility criteria for pregnancy prevention.

Document Date:

DAIDS TMF Index Guiding Principles

Document Date:

Dapivirine (Microbicide Gel)

Document Date:

Dapivirine (Vaginal Ring)

Document Date:

Dapivirine-Levonorgestrel (Vaginal Ring)

Document Date:

Darunavir (Prezista) Risk List

The following serious side effects have been associated with the use of darunavir given together with ritonavir (RTV). Contact your healthcare provider if you have any of the symptoms of liver problems that are listed and any skin changes with the symptoms listed below.

Document Date:

Darunavir/Cobicistat (Prezcobix) Package Insert

Document Date:

Delamanid (OPC-67683)

Document Date:

Didanosine (Videx EC) Risk List

The following side effects have been associated with the use of didanosine:

Document Date:

Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events - Changes Highlighted

Instructions for using the Table for Grading the Severity of Severity of Adult and Pediatric Adverse Events version 2.0. Changes are highlighted visually within the document.

Document Date:

Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Changes Highlighted Corrected Version 2.1, July 2017

Instructions for using the Table for Grading the Severity of Adult and Pediatric Adverse Events. Changes highlighted, Corrected version 2.1, July 2017

Document Date:

Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1, July 2017

Instructions for using the Table for Grading the Severity of Adult and Pediatric Adverse Events. Corrected version 2.1, July 2017

Document Date:

Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, v. 1.0

This clarification of the DAIDS Table for Grading the Severity of Adult and Pediatric AE’s provides additional explanation of the DAIDS AE Grading Table and clarifies some of the parameters.

Document Date:

Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, v. 2.0

Instructions for using the Table for Grading the Severity of Severity of Adult and Pediatric Adverse Events version 2.0. This version does not visually show changes with highlighting.

Document Date:

Division of AIDS Safety Office Expedited Adverse Event (EAE) Form

Expedited reporting form for Adverse Events fillable using Microsoft Word.

Document Date:

DNA Mosaic-Tre env DNA Vaccine

Document Date:

DNA-HIV-PT123

Document Date:

DNA-HIV-PT123/NYVAC-HIV-PT1/NYVAC-HIV-PT4 vaccine

Document Date:

Dolutegravir (GSK1349572)

Document Date:

Dolutegravir (Tivicay) Package Insert

TIVICAY is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 30 kg.

Document Date:

Dolutegravir (Tivicay) Risk List

DAIDS Core Risk List (side effects/risks of study drug) for Dolutegravir (DTG) version 2.0, September 2018 The DAIDS Core Risk Lists provides the DAIDS Medical Officer with a list of recommended risks (side effects) that will be used in the DAIDS Sample Informed Consent (SIC) Form. The list draws…

Document Date:

Doravirine (MK-1439)

Document Date:

Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A)

Document Date:

Doravirine (Pifeltro)

Document Date:

Edurant (rilpivirine) Tablets, Package Insert

EDURANT is a human immunodeficiency virus type 1 (HIV-1) specific, non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated - in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-naïve patients with HIV-1 RNA less than or equal to 100,000 copies/…

Document Date: